TORONTO, June 13, 2023— DAMONA Pharmaceuticals, a preclinical biopharmaceutical company focused on the discovery and development of first-in-class small molecules for the treatment and prevention of cognitive symptoms associated with brain disorders and aging, today announced the appointment of John Reilly as the company’s Chief Executive Officer and member of the Board of Directors. Mr.…
read moreDAMONA Pharmaceuticals was recently highlighted in a news article, prepared by Ben Gane, for the University of Toronto. This article highlights the creation of Damona by CAMH (the Centre of Addiction and Mental Health in Toronto) and Dr. Etienne Sibille. Full Article In this article, you can learn about the company’s achievements that have attracted…
read moreWe are delighted to announce that the Ontario Brain Institute (OBI) is investing approximately $400,000 CAD in Damona Pharmaceuticals, to provide support to the company developing treatments for cognitive deficits in depression and other brain disorders. DAMONA’s team is excited to engage with OBI, and thank them for their support.
read moreThrough a multicentered collaboration, joining experts from the Centre for Addiction and Mental Health (CAMH) and University Health Network (UHN), Yao and colleagues are presenting this new release, highlighting how depression impairs cortical inhibition and stimulus processing Find Article Cortical processing depends on finely tuned excitatory and inhibitory connections in neuronal microcircuits. Reduced inhibition by…
read moreLIVING WITH DEMENTIA – CTV Your Morning https://www.youtube.com/watch?v=8AVa1frLbyA From CTV Your Morning On September 16th, 2021, CTV Your Morning presented a media piece about memory loss and how CAMH contributes to tackling this issue. It introduces Paul Leah, an individual that had a stroke more than 10 years ago, damaging a quarter of his brain. Paul now lives…
read moreWhat could prevent suicide? For CAMH and mental health advocates, it’s advances in research and treatment. Article on TORONTO STAR What could prevent suicide? For CAMH and mental health advocates, it’s advances in research and treatment. For decades, suicide and mental health were taboo topics in most social circles. Opening upabout personal struggles was often…
read moreThe human brain, in all its complexity, is nearly impossible to model. Neuroscientists are trying anyway. Illustration by Jeremy Leung The WALRUS, Canadian general-interest magazine published a new piece on May 19th, 2021 about CAMH scientists working towards clarifying the impact of depression on our brain. The piece by writer Simon Lewsen, and beautifully illustrated by…
read moreFind out more about Dr. Sibille’s research at camh, and how it relates to Research & Development in AlphaCog. Link to Camh Website Long before the technology existed that allows CAMH scientists to observe what is actually going on in the living brain, none other than Dr. Sigmund Freud declared that the brains of people…
read moreThe paper was published by Fee et al. in the International Journal of Neuropsychopharmacology. Patients suffering from mood and anxiety disorders often exhibit a deficit in brain inhibition. This deficit in brain inhibition is due do dysfunctional somatostatin (SST) cells, causing mood and cognitive symptoms in patients. Using transgenic mice in which the SST cell…
read moreDrs. Prevot, Sibille and Colleagues just published their finding in the Journal Cerebral Cortex, about a new molecule reversing brain atrophy and memory dysfunction observed during aging. During aging, our brain tends to slowly shrink in size due to neuronal shrinkage and reduced function. This phenomenon participates in the emergence of cognitive and memory deficits,…
read more- 1
- 2